"The losers are the Genentech shareholders. Roche has just screwed anyone dumb enough to have bought over $82.50 a share," says one New York health care hedge fund manager who had no position in ...

The first of its kind runway show took place Sept. 8 as a prelude to the start of New York Fashion Week. Genentech partnered with Open Style Lab, a nonprofit organization that creates functional ...

I am a New Yorker, having spent most of my life in the New York metro area ... rather than a law firm revenue generator. How big is Genentech's in-house litigation department and how is it ...

“Most Likely Not To” yet again exemplifies Genentech’s steadfast support of the SMA community ... walked the runway as part of the Double Take Fashion Show during New York Fashion Week. The event was ...

The initial show, which is part of Genentech’s larger SMA My Way initiative, was held in September to coincide with New York Fashion Week. SMA, which is a rare disease that affects between 10,000 to ...

The next year, Genentech and people with SMA held the Double Take show as a prelude to New York Fashion Week. Adam Pryor, who leads neuroscience and rare disease public relations at Genentech ...

(RTTNews) - Genentech announced plans to invest more ... Inc. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors ...

WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments ...

Repertoire Immune Medicines has signed a partnership and licensing agreement with Roche’s Genentech ... “As we seek new opportunities to bring an even greater impact to patients, we look ...

See Correction/Clarification at the end of this article. The facility that produced the Genentech-defining cancer drugs Avastin and Herceptin as well as 10 others is stopping commercial manufacturing.

Genentech’s new stroke drug is delivered as a single five-second intravenous (IV) bolus, whereas Activase is administered as an IV bolus followed by a one-hour infusion. The differences in ...

May 12, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today plans to invest more than $700 million in a new 700,000 square foot state-of-the ...